Immuneering Corporation IMRX

4.27 (0.07) (1.61%) as of 25 Sep
Market cap
$280.8M
P/E
0.0×
Insider Buys alert about insiders buying in the last 12 month
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 Dec '17
P/E ratio
— — — 0.00 0.00 0.00 0.00 —
P/S ratio
— — — 333.79 105.83 33.89 33.89 —
P/FCF ratio
— — — 0.00 0.00 0.00 0.00 —
P/Operating CF
— — — (9.01) (23.82) (13.54) (13.54) —
P/B ratio
— — — 0.96 1.41 0.00 0.00 —
EV/Sales
— — — 0.91 34.10 14.35 14.35 —
EV/EBITDA
— — — 0.00 0.00 0.00 0.00 —
EV/FCF
— — — (0.01) (2.29) (1.71) (1.71) —
Current Ratio
17.50 5.28 11.35 13.50 27.04 16.73 27.83 —
Net Debt/EBITDA
2.94 0.57 1.46 2.06 4.44 2.18 (0.45) —
Debt/Equity
0.00 0.00 0.00 0.00 0.00 0.00 (2.54) —
ROE
(43.12%) (92.51%) (53.36%) (38.00%) (50.24%) 117.48% 53.15% —
ROA
(39.36%) (78.61%) (47.54%) (34.95%) (32.70%) (64.86%) (109.20%) —
ROIC
(81.29%) (763.99%) (743.47%) (747.69%) (312.34%) 0.00% 0.00% —
Return on Tangible Assets
(33.53%) (183.81%) (64.71%) (49.49%) (22.73%) (47.95%) (56.71%) —
Average Days of Receivables
— — — 14.28 43.17 78.97 39.91 —
Earnings Yield
— — — (47.88%) (23.24%) (25.50%) (25.50%) —
Free Cash Flow Yield
— — — (42.38%) (14.04%) (24.78%) (24.78%) —
Free Cash Flow per Share
(1.03) (1.84) (1.74) (1.70) (2.27) (2.96) (0.18) —
Book value per Share
4.96 1.38 3.19 4.16 11.46 (4.54) (0.26) —
Free Cash Flow
(45.49) (55.08) (49.31) (44.84) (30.91) (14.67) (4.50) —
EV/EBIT
— — — 0.00 0.00 0.00 0.00 —
Other line items

Show all line items

Columns are period end dates